Intercept Pharmaceuticals Inc., is a clinical stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases.
Current News
  • July 28, 2010 - Intercept Pharmaceuticals to Collaborate with NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH) ...More »


  • April 13, 2010 - Intercept Pharmaceuticals Presents Positive Phase II Results from Study of INT-747 Therapy in Primary Biliary Cirrhosis at EASL...More »


  • January 25, 2010 - Intercept Pharmaceuticals Raises $25 Million Series B Financing, Dr. Lorenzo Tallarigo Appointed Chairman More »


  • October 27, 2009 - Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for
    Primary Biliary Cirrhosis More »


  • October 2, 2009 - Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease More »


  • September 2, 2009 - Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity ... More »


  • August 7th, 2008 - Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling ... More »
Upcoming Events
  • August 3, 2010 - Intercept Pharmaceuticals, Inc. will be presenting at the Wedbush Securities Life Sciences Best Ideas MAC: Management Access Conference in New York on Tuesday, August 3, 2010 at 1:35 p.m. ET. Dr. Mark Pruzanski, CEO and President, will provide a corporate overview.